Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
AEOLUS PHARMACEUTICALS, INC. (AOLS)
|
Add to portfolio |
|
|
|
| Price: |
$0.00
| | Metrics |
| OS: |
152.1
|
M
| |
-4401
|
% ROE
|
| Market cap: |
|
| |
|
|
|
Net cash:
|
$403
|
k
| |
$0.00
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($4.1)
|
M
| |
|
|
|
EBIT
|
($4.1)
|
M
| |
|
|
| EPS |
($20.23)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Sep-30-16 | Sep-30-15 | Sep-30-14 | Sep-30-13 | Sep-30-12 | Sep-30-11 | Sep-30-10 | Dec-31-09 |
| Revenues | 2.1 | 3.1 | 9.6 | 3.9 | 7.3 | 4.8 | 0.0 | 0.0 |
| Revenue growth | -33.3% | -67.7% | 145.2% | -46.1% | 51.3% | | -100.0% | |
| Cost of goods sold | 5.3 | 5.7 | 9.7 | 6.6 | 9.7 | 8.7 | 0.0 | 0.0 |
| Gross profit | -3.3 | -2.6 | -0.1 | -2.7 | -2.4 | -3.9 | 0.0 | 0.0 |
| Gross margin | -157.7% | -84.4% | -0.8% | -68.7% | -32.5% | -80.9% | | |
| Research and development | 2.9 | 3.5 | 7.0 | 3.4 | 6.5 | 5.1 | 1.7 | 0.7 |
| General and administrative | 2.6 | 2.4 | 3.4 | 4.1 | 3.8 | 4.6 | 2.0 | 1.3 |
| EBIT | -3.3 | -2.6 | -0.1 | -2.7 | -2.4 | -3.9 | -3.6 | -2.0 |
| EBIT margin | -157.7% | -84.4% | -0.8% | -68.7% | -32.5% | -80.9% | | |
| Pre-tax income | -3.6 | -2.6 | -0.1 | -3.2 | 1.7 | 0.3 | -25.9 | -2.3 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | | | | 0.1% | 0.7% | 0.0% | 0.0% |
| Net income | -6.0 | -2.6 | -0.1 | -3.2 | 0.9 | 0.3 | -25.9 | -2.3 |
| Net margin | -291.1% | -84.5% | -0.8% | -81.7% | 11.7% | 6.2% | | |
| |
| Diluted EPS | ($0.04) | ($0.02) | ($0.59) | ($0.03) | $12.05 | $5.03 | ($0.53) | ($66.00) |
| Shares outstanding (diluted) | 148.7 | 135.9 | 0.1 | 106.6 | 0.1 | 0.1 | 49.2 | 0.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|